Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Lexicon Pharmaceuticals fourth quarter and full year 2025 financial results conference call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a brief question and answer session. As a reminder, this call is being recorded today, March 5th, 2026. I would now like to turn the call over to Lisa DeFrancesco, SVP Investor Relations and Corporate Communications for Lexicon. Please go ahead, Lisa. Thank you, Michelle. Good morning and welcome to our Q4 and full year 2025 earnings conference call. Joining me today are Dr. Mike Exton, Lexicon's Chief Executive Officer and Director, Dr. Craig Granowitz, Senior Vice President and Chief Medical Officer, and Scott Chianti, Senior Vice President and Chief Financial Officer. This morning, Lexicon issued a press release announcing our financial results for the fourth quarter and full year of 2025, which is available on our website at www.lexpharma.com and through our SEC filings. A webcast of this call, along with a slide presentation, is also available on our website. During this call, we will review the information provided in the release provide a corporate update, and then use the remainder of our time to answer your questions. Before we begin, let me remind you that we will be making forward-looking statements, including statements related to the safety, efficacy, clinical development, regulatory status, and therapeutic and commercial potential of Sotocliflozin, Pilavapidin, LX9851, and our other drug programs, as well as our business generally. These statements may include characterizations and projections related to the clinical development, regulatory status, market opportunity for our drug programs, commercial performance of IMPEFA for heart failu...